YungShin Global Holding Corporation (TPE:3705)
57.80
-1.10 (-1.87%)
Nov 19, 2026, 1:30 PM CST
YungShin Global Holding Revenue
YungShin Global Holding had revenue of 2.01B TWD in the quarter ending September 30, 2026, with 5.22% growth. This brings the company's total for the last twelve months to 7.94B, down -5.14% year-over-year. In the year 2025, YungShin Global Holding had annual revenue of 8.38B with 4.28% growth. That makes YungShin Global Holding the 16,151st largest company in the world by revenue and 566th in Taiwan.
Revenue (ttm)
7.94B
Revenue Growth
-5.14%
P/S Ratio
1.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.40B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full YungShin Global Holding breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.38B | 343.95M | 4.28% |
| Dec 31, 2024 | 8.03B | 1.00B | 14.29% |
| Dec 31, 2023 | 7.03B | -283.83M | -3.88% |
| Dec 31, 2022 | 7.31B | -493.29M | -6.32% |
| Dec 31, 2021 | 7.81B | -279.61M | -3.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 31.08B |
| Bora Pharmaceuticals | 21.20B |
| Standard Chemical & Pharmaceutical | 7.23B |
| TTY Biopharm Company | 6.81B |
| Synmosa Biopharma | 6.68B |
| Formosa Laboratories | 4.82B |
| ScinoPharm Taiwan | 3.04B |
| Center Laboratories | 1.78B |